CELLIVERY

ABOUT US

HISTORY

히스토리이미지

STORY OF
CELLIVERY

Cellivery Therapeutics Inc. was founded by Dr. Daewoong Jo, President and CEO in March of 2014. Its earliest notions have been prepared, however, when Dr. Jo began to study for his doctoral thesis at Vanderbilt University, Nashville, TN, USA in 1997.

Dr. Daewoong Jo is a long-time expert of the cutting-edge technology-based biotech industry who has experienced more than 18 years as scientist, professor and businessman in US and Korea. He contributed to multiple numbers of protein-based new drug discovery by using TSDT platform he mastered for innovative new drug development. His extensive knowledge and experience in TSDT platform, its application to various fields of biomedical sciences and businesses make him and his colleagues excellent resource for the Company as we prepare to advance our mission into pivotal drug development.

  • 2019

    Completion of USA CP-△SOCS3 Obesity Therapy Patent Registration US(10323072)

    Completion of Korea aMTD/TSDT Platform Patent Registration KR(101971021)

    Completion of USA aMTD/TSDT Platform Patent Registration US(10323063)

    Completion of Japan aMTD/TSDT Platform Patent Registration JP(6559227)

    Completion of USA iCP-SOCS3 Hepatocellular Carcinoma Therapy Patent Registration US(10385103)

    Completion of Australia iCP-Parkin Parkinson's Disease Therapy Patent Registration AU(2016299468)

    Completion of USA iCP-RFs iPSC Reprogramming Factors Patent Registration US(15/884651)

    Completion of USA CP-BMP2 Bone Healing Therapy Patent Registration US(15/884884)

    Completion of EU iCP-Parkin Parkinson's Disease Therapy Patent Registration EP(16830820.3)

    Completion of EU iCP-RFs iPSC Reprogramming Factors Patent Registration EP(16835416.5)

  • 2018

    Completion of Australia aMTD/TSDT Platform Patent Registration AU(2015304194)

    Cellivery Therapeutics, to be listed on KOSDAQ

    「Research Collaboration」 with one of the Top 10 Global Big Pharma

    「Feasibility Study」 with one of the Top 40 Global Big Pharma

    「Research Collaboration」 with one of the Top 20 Global Big Pharma

    Grant Support from Small and Medium Business Administration (Grant ID: S2579740)

    Grant Support from Ministry of Health & Welfare (Grant ID: H18C1986)

    Grant Support from Korea Intellectual Property Strategy Agency (Grant ID: 18IC41C019)

    Began Preclinical/Clinical Trials of Anti-Pancreatic Cancer Agent

    CDA/MTA/FSA Executed with one of the Top 20 Global Big Pharma

    CDA/MTA/FSA Executed with one of the Top 40 Global Big Pharma

    11’th Equity Investment

  • 2017

    Grant Support from Michael J. Fox Foundation Core Funding Programs (Grant ID: MJFF14241)

    Grant Support from Small and Medium Business Administration (Global Star Venture R&D Project, Project ID: S2516999)

    Grant Support from Small and Medium Business Administration (Cooperation Equipment Application Plan, Project ID: C0486076)

    Began Preclinical/Clinical Trials of Anti-Parkinson's Disease Agent

    CDA/MTA/FSA Executed with one of the Top 20 Global Big Pharma

    CDA/MTA/FSA Executed with one of the Major Global Distributor

    10th Equity Investment

  • 2016

    Commercialization of Research Reagents (iCP-Cre&iCP-RFs)

    Grant Support from Small and Medium Business Administration

    Grant Support from Ministry of Trade, Industry and Energy

    9th Equity Investment

    Collaboration Agreement with Ildong Pharmaceuticals Co., Ltd.

    Agreement on Collaboration for Research Reagent Commercialization with Daejung Chemicals & Metals Co., Ltd.

  • 2015

    6~8th Equity Investment

    Research & Business Partnering with Vanderbilt University

    Dr. Earl Ruley Joined as Company's Science & Business Advisor

    Grant Support from Small and Medium Business Administration

    13 Patent Applications: TSDT Platform & Protein-Based Biotherapeutics (Anti-Cancer Agent, Anti-Neurodegenerative Disease Agent, Pro-Osteogenetic Agent, Anti-Obesity Agent) and Research Reagents (iCP-Cre&iCP-RFs)

  • 2014

    4~5th Equity Investment

    Headquater Relocated in Seoul

    4 Patent Application in TSDT & 3 Drug Candidates

    R&D Fund Support from Ministry of Science, ICT and Future Planning

    1st ~ 3rd Equity Investment

    Cellivery Therapeutics, Inc. Founded in Busan, Korea

    Published Papers about Stem Cell Therapy and Parkinson's Disease in Scientific Reprots and PLoS ONE

  • 2013

    Published papers about Cancer Therapy in Clinical Cancer Research and Biomaterials

  • 2012

    Published a paper about Cancer Therapy in Molecular Therapy

  • 2011

    Published about Protein Replacement Therapy in Cancer Research

    Dr. Jo took sabbatical leave at Vanderbilt Univ& collaborated with El-Rifai group

  • 2006

    Dr. Jo came back to Korea to take professorship at Chonnam National University Medical School

    The first TSDT-based bioventure company founded by Dr. Jo